Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.69 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.69 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.68 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CFTR | P13569 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475801 | 1.00 | GABRA1 (0.69) | GABRA1GABRB2CLEC4MGABRB1GABRA3 | |
| Hydrochloric Acid SCHEMBL29008098 | 0.99 | GABRA1 (0.67) | GABRA1GABRB2CLEC4MGABRB1GABRA3 | |
| Hydrochloric Acid SCHEMBL30417898 | 0.99 | GABRA1 (0.67) | GABRA1GABRB2CLEC4MGABRB1GABRA3 | |
| SCHEMBL730525 | 0.89 | NR4A2 (0.69) | GABRA1GABRB2KDM4EMEN1KMT2A | |
| SCHEMBL22704179 | 0.89 | GABRA1 (0.61) | GABRA1GABRB2CLEC4MGABRB1GABRA3 | |
| Hydrochloric Acid SCHEMBL28308377 | 0.88 | NR4A2 (0.67) | GABRA1GABRB2KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30718988 | 0.88 | NR4A2 (0.67) | GABRA1GABRB2KDM4EMEN1KMT2A | |
| SCHEMBL7515095 | 0.84 | NR4A2 (0.60) | GABRA1GABRB2GABRB1GABRA3CFTR | |
| SCHEMBL29696613 | 0.83 | NR4A2 (0.79) | GABRA1GABRB2CFTR | |
| SCHEMBL2052030 | 0.83 | NR4A2 (0.79) | GABRA1GABRB2CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4043439-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-03-12 | — | — | EP | claimed |
| EP-3464243-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-02-12 | — | — | EP | claimed |
| EP-4043439-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR [ | Council of Scientific and Industrial Research (IN) | 2022-08-17 | — | — | EP | claimed |
| US-11274081-B2 | Process for the synthesis of ivacaftor | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-03-15 | — | — | US | claimed |
| CN-108675959-B | Deuterated enrofloxacin-d5Preparation method of (1) | 雅安职业技术学院 | 2022-02-25 | — | — | CN | claimed |
| US-20200325104-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-10-15 | — | — | US | claimed |
| CN-111646941-A | Sulfonamide derivative and preparation method and application thereof | 天津科技大学 | 2020-09-11 | — | — | CN | claimed |
| EP-3464243-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | Council of Scientific and Industrial Research (IN) | 2019-04-10 | — | — | EP | claimed |
| WO-2017208253-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-12-07 | — | — | WO | claimed |
| EP-4556008-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4043439-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-03-12 | — | — | EP | disclosed |
| EP-3464243-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-02-12 | — | — | EP | disclosed |
| EP-3470063-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMA (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024151425-A1 | COMPOUNDS AND METHOD FOR TREATING HIV INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-18 | — | — | WO | disclosed |
| US-4659734-A | BACTERICIDES, FUNGICIDES | NIPPON SHINYAKU CO., LTD. (JP) | 1987-04-21 | — | — | US | disclosed |
| EP-0058392-B1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1985-11-21 | — | — | EP | disclosed |
| EP-0055068-B1 | QUINOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Lilly Industries Limited (GB) | 1984-10-17 | — | — | EP | disclosed |
| US-4390541-A | ANTIALLERGENS; ANTISPASMODIC AGENTS | LILLY INDUSTRIES LIMITED (GB) | 1983-06-28 | — | — | US | disclosed |
| EP-0058392-A1 | Substituted carboxylic acid derivatives | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1982-08-25 | — | — | EP | disclosed |
| EP-0055068-A1 | Quinolone derivatives and their use as pharmaceuticals | Lilly Industries Limited (GB) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274081-B2 | Process for the synthesis of ivacaftor | IDO1, IDO2, SLC10A2 | GABRA1 946/4885GABRB2 1587/4885CLEC4M 2943/4885 |
| US-20200325104-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | IDO1, SLC10A2, IDO2 | GABRA1 952/4885GABRB2 1472/4885CLEC4M 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.